Telos Rx vs MadeMed
Two GLP-1 desks, one scoreboard. We put Telos Rx and MadeMed head-to-head on the published Brief Score — the same six factors, scored the same way.
MadeMed
The verdict
MadeMed takes this head-to-head.
MadeMed scores 86 to 85 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.
That doesn't make Telos Rx a bad call — it's best for readers who want glp-1 care and a needle-free oral or microdosed route on the same certified desk that also carries peptides, nad+ and hrt — and will trade fda-approved brand access and up-front pricing for the deepest menu at the lowest annual-lock rate. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Telos Rx | MadeMed | |
|---|---|---|
| Brief Score | 85/100 (B) | 86/100 (B) |
| Semaglutide | $49/mo (microdosed, annual) | $239/mo injectable · $219/mo sublingual (quarterly) |
| Tirzepatide | $99/mo (annual) | $399/mo injectable · $299/mo sublingual (quarterly) |
| Coverage | Not publicly listed | 40 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
Telos Rx: Headline GLP tiers held flat this cycle, but the $49 microdosed and $99 tirzepatide rates are annual-lock prices — short-term plans run meaningfully higher, and everything outside GLP-1 stays unpriced until intake.
MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.